218 related articles for article (PubMed ID: 19433838)
1. Cumulative incidence of false-positive results in repeated, multimodal cancer screening.
Croswell JM; Kramer BS; Kreimer AR; Prorok PC; Xu JL; Baker SG; Fagerstrom R; Riley TL; Clapp JD; Berg CD; Gohagan JK; Andriole GL; Chia D; Church TR; Crawford ED; Fouad MN; Gelmann EP; Lamerato L; Reding DJ; Schoen RE
Ann Fam Med; 2009; 7(3):212-22. PubMed ID: 19433838
[TBL] [Abstract][Full Text] [Related]
2. Overall and Multiphasic Findings of the Prostate, Lung, Colorectal and Ovarian (PLCO) Randomized Cancer Screening Trial.
Prorok PC; Wright P; Riley TR; Kramer BS; Berg CD; Gohagan JK
Rev Recent Clin Trials; 2018; 13(4):257-273. PubMed ID: 29629665
[TBL] [Abstract][Full Text] [Related]
3. The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial of the National Cancer Institute: history, organization, and status.
Gohagan JK; Prorok PC; Hayes RB; Kramer BS;
Control Clin Trials; 2000 Dec; 21(6 Suppl):251S-272S. PubMed ID: 11189683
[TBL] [Abstract][Full Text] [Related]
4. Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up.
Andriole GL; Crawford ED; Grubb RL; Buys SS; Chia D; Church TR; Fouad MN; Isaacs C; Kvale PA; Reding DJ; Weissfeld JL; Yokochi LA; O'Brien B; Ragard LR; Clapp JD; Rathmell JM; Riley TL; Hsing AW; Izmirlian G; Pinsky PF; Kramer BS; Miller AB; Gohagan JK; Prorok PC;
J Natl Cancer Inst; 2012 Jan; 104(2):125-32. PubMed ID: 22228146
[TBL] [Abstract][Full Text] [Related]
5. Design of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial.
Prorok PC; Andriole GL; Bresalier RS; Buys SS; Chia D; Crawford ED; Fogel R; Gelmann EP; Gilbert F; Hasson MA; Hayes RB; Johnson CC; Mandel JS; Oberman A; O'Brien B; Oken MM; Rafla S; Reding D; Rutt W; Weissfeld JL; Yokochi L; Gohagan JK;
Control Clin Trials; 2000 Dec; 21(6 Suppl):273S-309S. PubMed ID: 11189684
[TBL] [Abstract][Full Text] [Related]
6. Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial.
Buys SS; Partridge E; Black A; Johnson CC; Lamerato L; Isaacs C; Reding DJ; Greenlee RT; Yokochi LA; Kessel B; Crawford ED; Church TR; Andriole GL; Weissfeld JL; Fouad MN; Chia D; O'Brien B; Ragard LR; Clapp JD; Rathmell JM; Riley TL; Hartge P; Pinsky PF; Zhu CS; Izmirlian G; Kramer BS; Miller AB; Xu JL; Prorok PC; Gohagan JK; Berg CD;
JAMA; 2011 Jun; 305(22):2295-303. PubMed ID: 21642681
[TBL] [Abstract][Full Text] [Related]
7. Flexible sigmoidoscopy in the randomized prostate, lung, colorectal, and ovarian (PLCO) cancer screening trial: added yield from a second screening examination.
Weissfeld JL; Schoen RE; Pinsky PF; Bresalier RS; Doria-Rose VP; Laiyemo AO; Church T; Yokochi LA; Yurgalevitch S; Rathmell J; Andriole GL; Buys S; Crawford ED; Fouad M; Isaacs C; Lamerato L; Reding D; Prorok PC; Berg CD;
J Natl Cancer Inst; 2012 Feb; 104(4):280-9. PubMed ID: 22298838
[TBL] [Abstract][Full Text] [Related]
8. Quality control of cancer screening examination procedures in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial.
Weissfeld JL; Fagerstrom RM; O'Brien B;
Control Clin Trials; 2000 Dec; 21(6 Suppl):390S-399S. PubMed ID: 11189690
[TBL] [Abstract][Full Text] [Related]
9. Overall mortality in men and women in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial.
Pinsky PF; Miller EA; Zhu CS; Prorok PC
J Med Screen; 2019 Sep; 26(3):127-134. PubMed ID: 30943843
[No Abstract] [Full Text] [Related]
10. Assessing contamination and compliance in the prostate component of the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial.
Pinsky PF; Blacka A; Kramer BS; Miller A; Prorok PC; Berg C
Clin Trials; 2010 Aug; 7(4):303-11. PubMed ID: 20571134
[TBL] [Abstract][Full Text] [Related]
11. Association of Nonadherence to Cancer Screening Examinations With Mortality From Unrelated Causes: A Secondary Analysis of the PLCO Cancer Screening Trial.
Pierre-Victor D; Pinsky PF
JAMA Intern Med; 2019 Feb; 179(2):196-203. PubMed ID: 30592477
[TBL] [Abstract][Full Text] [Related]
12. Update of the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial.
Andriole GL
Recent Results Cancer Res; 2014; 202():53-7. PubMed ID: 24531777
[TBL] [Abstract][Full Text] [Related]
13. Prostate Cancer Screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial: findings from the initial screening round of a randomized trial.
Andriole GL; Levin DL; Crawford ED; Gelmann EP; Pinsky PF; Chia D; Kramer BS; Reding D; Church TR; Grubb RL; Izmirlian G; Ragard LR; Clapp JD; Prorok PC; Gohagan JK;
J Natl Cancer Inst; 2005 Mar; 97(6):433-8. PubMed ID: 15770007
[TBL] [Abstract][Full Text] [Related]
14. Cumulative incidence of false-positive test results in lung cancer screening: a randomized trial.
Croswell JM; Baker SG; Marcus PM; Clapp JD; Kramer BS
Ann Intern Med; 2010 Apr; 152(8):505-12, W176-80. PubMed ID: 20404381
[TBL] [Abstract][Full Text] [Related]
15. Pathologic findings following false-positive screening tests for ovarian cancer in the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial.
Nyante SJ; Black A; Kreimer AR; Duggan MA; Carreon JD; Kessel B; Buys SS; Ragard LR; Johnson KA; Dunn BK; Lamerato L; Commins JM; Berg CD; Sherman ME
Gynecol Oncol; 2011 Mar; 120(3):474-9. PubMed ID: 21144559
[TBL] [Abstract][Full Text] [Related]
16. The economic impact of false-positive cancer screens.
Lafata JE; Simpkins J; Lamerato L; Poisson L; Divine G; Johnson CC
Cancer Epidemiol Biomarkers Prev; 2004 Dec; 13(12):2126-32. PubMed ID: 15598770
[TBL] [Abstract][Full Text] [Related]
17. Secondary prostate cancer screening outcomes by race in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Screening Trial.
Miller EA; Pinsky PF; Black A; Andriole GL; Pierre-Victor D
Prostate; 2018 Aug; 78(11):830-838. PubMed ID: 29667217
[TBL] [Abstract][Full Text] [Related]
18. False-positive cancer screens and health-related quality of life.
McGovern PM; Gross CR; Krueger RA; Engelhard DA; Cordes JE; Church TR
Cancer Nurs; 2004; 27(5):347-52. PubMed ID: 15525861
[TBL] [Abstract][Full Text] [Related]
19. Prostate biopsy following a positive screen in the prostate, lung, colorectal and ovarian cancer screening trial.
Pinsky PF; Andriole GL; Kramer BS; Hayes RB; Prorok PC; Gohagan JK;
J Urol; 2005 Mar; 173(3):746-50; discussion 750-1. PubMed ID: 15711261
[TBL] [Abstract][Full Text] [Related]
20. Prognostic Significance of Digital Rectal Examination and Prostate Specific Antigen in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Arm.
Halpern JA; Shoag JE; Mittal S; Oromendia C; Ballman KV; Hershman DL; Wright JD; Shih YT; Nguyen PL; Hu JC
J Urol; 2017 Feb; 197(2):363-368. PubMed ID: 27569432
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]